Background Cohort studies have described the short‐term effectiveness and safety of
vedolizumab in treating patients with Crohn's disease (CD) and ulcerative colitis (UC), but …

Background We recently showed that vedolizumab is effective in patients with Crohn's
disease (CD) and ulcerative colitis (UC) with prior anti‐TNF failure in a multicentre …

Background Vedolizumab has become a standard treatment for the inflammatory bowel
diseases ulcerative colitis (UC) and Crohn's disease (CD). However, there is an ongoing …

Background Vedolizumab (VDZ) has demonstrated long-term efficacy in Crohn's disease
(CD) and ulcerative colitis (UC) in phase III trials. Aims Our aim was to evaluate the efficacy …

Background Vedolizumab is approved for moderate to severe Crohn's disease (CD) and
ulcerative colitis (UC). We present prospective, 1-year data of the real-world effectiveness …

Background Effectiveness of vedolizumab in real world clinical practice is unknown. Aim To
evaluate the short and long‐term effectiveness of vedolizumab in patients with inflammatory …

Abstract Background and Aims Many observational studies on the use of vedolizumab [VDZ]
in patients with Crohn's disease [CD] and ulcerative colitis [UC] have been published in the …

Background: Data on vedolizumab (VDZ) use in inflammatory bowel disease (IBD) patients
are still limited. We aimed to assess the effectiveness and tolerability of VDZ in a real-life …

Background & Aims Phase 3 trials have shown the efficacy of vedolizumab, which binds to
integrin α4β7, in patients with Crohn's disease (CD) or ulcerative colitis (UC). We …

Prospective data of vedolizumab treatment for patients with inflammatory bowel disease
(IBD) beyond 1 year of treatment is scarce but needed for clinical decision making. We …